Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

UnitedHealth seeks more clarity on Biogen's $56,000 Alzheimer's drug coverage

Stock MarketsJul 15, 2021 12:11PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The corporate logo of the UnitedHealth Group appears on the side of one of their office buildings in Santa Ana, California, U.S., April 13, 2020. REUTERS/Mike Blake/File Photo

By Manojna Maddipatla

(Reuters) - UnitedHealth Group Inc (NYSE:UNH) said it needed more time to determine its coverage policy for Biogen's recently approved $56,000 Alzheimer's disease drug Aduhelm that is expected to raise costs for the U.S. government Medicare program.

The government's Medicare program and private health insurers such as UnitedHealth, which sell Medicare Advantage plans for those aged above 65 and are known to be susceptible to Alzheimer's disease, will be affected as they will have to bear most of the drug cost.

UnitedHealth said it was awaiting guidance on coverage from the Centers for Medicare and Medicaid Services, which earlier this week began its review process to cover the drug's cost under the Medicare program.

Biogen Inc (NASDAQ:BIIB)'s shares dropped about 5% after the comments on Aduhelm, which won the U.S. health regulator's nod last month despite strong objection from its expert advisory panel over lack of sufficient clinical evidence on the drug's effectiveness.

Wall Street analysts estimated peak annual sales of $10 billion to $50 billion for Aduhelm.

UnitedHealth on Thursday also raised its full-year earnings target for the second time this year, after a strong performance mainly in its Optum unit helped it beat second-quarter profit expectations.

The 2021 profit forecast of $18.30 to $18.80 per share includes a potential negative impact of $1.80 per share related to COVID-19 costs, which the company expects to record mostly in the back-half of the year.  

The guidance was conservative and leaves room for potential deferred care or COVID-19 costs in the back half of the year given uncertainty around the pandemic, Evercore ISI analyst Michael Newshel said.

The company said use of healthcare services, which trended below normal levels as patients put off non-urgent care during the height of pandemic, rebounded close to usual levels in the second quarter, especially in its employer-sponsored health plan business.

UnitedHealth seeks more clarity on Biogen's $56,000 Alzheimer's drug coverage
 

Related Articles

Goeasy: Has the Easy Money Already Been Made?
Goeasy: Has the Easy Money Already Been Made? By TipRanks - Sep 27, 2021

Goeasy (GSY) is a Canadian alternative financial service solution provider that's been on a magnificent run. The incredible appetite for BNPL (Buy Now, Pay Later) options, and...

4 Buy-rated Software Stocks to Add to Your Portfolio
4 Buy-rated Software Stocks to Add to Your Portfolio By StockNews - Sep 27, 2021

Ongoing digitalization in almost every industry, and the unabating remote working trend, should drive the demand for advanced and efficient software products and solutions....

3 Top Chemicals Stocks for September
3 Top Chemicals Stocks for September By StockNews - Sep 27, 2021

As the chemical industry is expected to keep growing despite supply chain challenges, it could be wise to bet on quality chemical stocks Dow (DOW), ICL Group (ICL), and NewMarket...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
karl burwick
karl burwick Jul 15, 2021 12:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Biden needs to fast-track this, for his own sake.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email